On July 10, WuXi Biologics rose 3.45% in regular trading, trading at HKD 38.28/share, with turnover of HKD 147 million.

On the news front, the company's MFG8 drug substance manufacturing facility successfully passed the U.S. FDA Pre-License Inspection (PLI), marking a critical milestone toward commercial supply of a potential blockbuster autoimmune therapy. The certification validates the facility's compliance with international high-standard manufacturing quality systems, paving the way for large-scale, stable drug production. The approval of the related therapy is expected to accelerate accordingly.

Additionally, UBS previously raised its target price for WuXi Biologics to HKD 51.1, maintaining a Buy rating, implying significant upside from the current share price. The company has also maintained a high-frequency buyback pace, repurchasing approximately HKD 99.82 million worth of shares on July 7 alone, with cumulative buybacks reaching HKD 1.272 billion year-to-date.

Within the Life Sciences Tools and Services sector, WUXI APPTEC up 3.69%, PHARMARON up 4.55%, WUXI XDC up 2.02%, XTALPI up 0.26%, INSILICO down 1.46%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)